Porownywarka

Epithalon vs Cartalax side-by-side

Zestaw do czterech peptydów według statusu dowodów, mechanizmów, dawkowania z badań, skutków ubocznych i referencji.

Wybrane (2/4)

EpithalonCartalax

Udostępnij porównanie peptydów

Wlasciwosc	Epithalon	Cartalax
Kategoria	Bioregulatory	Bioregulatory
Znany tez jako	Epitalon, Epithalone, AGAG	Ala-Glu-Asp, AED Tripeptide
Zatwierdzony przez FDA	Nie	Nie
Status kliniczny	Investigational; primarily Russian research. Source notes current FDA Category 2 status pending formal reclassification activity in 2026. Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA	Available in Russia; not FDA approved Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA
Czego oczekiwac	Longevity, telomere support, anti-aging, sleep	Joint health, cartilage support, osteoarthritis
Jak dziala	Epithalon is proposed to act through telomerase-related biology, with cell-culture reports describing telomerase activity and telomere elongation in human fibroblasts. The source also notes possible effects on melatonin, antioxidant defenses, and gene expression in pineal-hypothalamic pathways. Translation from these observations to meaningful human anti-aging outcomes remains unproven in the supplied evidence.	Cartalax is presented as AED, a short cytogen peptide for which the main proposed action is modulation of cartilage-cell gene activity. The cited source connects AED with chondrogenic markers such as SOX9, COL2 and ACAN and discusses WNT, ERK-p38 and Smad signaling in cartilage differentiation research. The evidence base described is centered on Khavinson-group and related preclinical work, so the mechanism should be treated as a research hypothesis rather than a clinically proven pathway.
Typowe dawkowanie	5-10 mg daily for 10-20 days · Once daily in cycles · 10-20 days	Limited community data available · See research protocols
Dawkowanie z badań	5-10 mg daily for 10-20 days · 10-20 day cycles · Subcutaneous or intramuscular injection	10-20 mg daily · 10-30 day courses · Oral
Typowy czas trwania	10-20 day cycles	10-30 day courses
Podanie	Subcutaneous or intramuscular injection	Oral
Timing	Before bed With or without food	Morning or as directed With or without food
Poziom dowodów	Badania kliniczne	Przedkliniczne
Mozliwe skutki uboczne	Generally well-tolerated (Reported in the source, but tolerability evidence is limited by the available research base.) Injection site reactions (Reported as a possible effect with injectable administration.) Mild headache (Source describes this as transient.) +3 więcej Sleep disturbances (Reported as a possible effect; frequency is not established.) Risk of immunogenicity (Listed as a potential risk rather than a quantified event rate.) Long-term safety not established (The source explicitly notes uncertainty about long-term safety.)	Generally well-tolerated (Reported by the source, but safety documentation is limited.) Mild injection site reactions (Listed as a mild reported effect.) Transient fatigue (Listed as a reported transient effect.) +2 więcej Mild gastrointestinal upset (Described by the source as rare.) Limited documented side-effect data (The source indicates that adverse-effect reporting is incomplete.)
Podsumowanie researchu	The supplied research narrative gives greatest weight to laboratory and animal data. It cites a 2003 report by Khavinson and colleagues on telomerase activity and telomere changes in cultured human fibroblasts, plus a 2025 review discussing geroprotective and neuroendocrine research. Animal studies are described as reporting lifespan and tumor-incidence findings. Human evidence is characterized as limited, often small or open-label, and not independently replicated at the scale needed to prove lifespan extension or reliable telomere-length effects in people.	The supplied research summary places Cartalax in a preclinical evidence category. It cites in-vitro and animal findings, including a 2023 review that discusses AED among peptides relevant to chondrogenic differentiation and cartilage-cell signaling. Reported Russian literature describes cartilage-protective and matrix-related effects, while the source also notes limited independent Western validation and no human clinical trials. Overall, the evidence supports biological plausibility in experimental systems, not demonstrated human benefit.
Referencje	PubMed PubMed +2 więcej WikipediaEpitalon Springer	Peptibase peptides Peptibase peptides +1 więcej Peptibase peptides
Pełny profil	Zobacz szczegóły	Zobacz szczegóły

Zapisz to porównanie

Trzymaj ten zestaw researchowy pod reka na darmowym koncie PeptiGuide.

Zapisz porównanie - darmowe konto

Trackuj swoja ścieżkę peptydówa

Zamien research w prywatny log protokołu, gdy będziesz gotowy.

Trackuj ścieżkę peptydówa

Wyłącznie edukacyjnie. Te informacje są agregowane z publicznych badań i raportów społeczności. To nie jest poradą medyczną, a informacje o dawkowaniu są opisowe, nie rekomendacyjne. Zawsze konsultuj się z wykwalifikowanym specjalistą ochrony zdrowia.

Wlasciwosc

Epithalon

Cartalax

Kategoria

Bioregulatory

Znany tez jako

Epitalon, Epithalone, AGAG

Ala-Glu-Asp, AED Tripeptide

Zatwierdzony przez FDA

Nie

Status kliniczny

Investigational; primarily Russian research. Source notes current FDA Category 2 status pending formal reclassification activity in 2026.

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

Available in Russia; not FDA approved

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

Czego oczekiwac

Longevity, telomere support, anti-aging, sleep

Joint health, cartilage support, osteoarthritis

Jak dziala

Epithalon is proposed to act through telomerase-related biology, with cell-culture reports describing telomerase activity and telomere elongation in human fibroblasts. The source also notes possible effects on melatonin, antioxidant defenses, and gene expression in pineal-hypothalamic pathways. Translation from these observations to meaningful human anti-aging outcomes remains unproven in the supplied evidence.

Cartalax is presented as AED, a short cytogen peptide for which the main proposed action is modulation of cartilage-cell gene activity. The cited source connects AED with chondrogenic markers such as SOX9, COL2 and ACAN and discusses WNT, ERK-p38 and Smad signaling in cartilage differentiation research. The evidence base described is centered on Khavinson-group and related preclinical work, so the mechanism should be treated as a research hypothesis rather than a clinically proven pathway.

Typowe dawkowanie

5-10 mg daily for 10-20 days · Once daily in cycles · 10-20 days

Limited community data available · See research protocols

Dawkowanie z badań

5-10 mg daily for 10-20 days · 10-20 day cycles · Subcutaneous or intramuscular injection

10-20 mg daily · 10-30 day courses · Oral

Typowy czas trwania

10-20 day cycles

10-30 day courses

Podanie

Subcutaneous or intramuscular injection

Oral

Timing

Before bed

With or without food

Morning or as directed

With or without food

Poziom dowodów

Badania kliniczne

Przedkliniczne

Mozliwe skutki uboczne

Generally well-tolerated (Reported in the source, but tolerability evidence is limited by the available research base.)
Injection site reactions (Reported as a possible effect with injectable administration.)
Mild headache (Source describes this as transient.)

+3 więcej

Sleep disturbances (Reported as a possible effect; frequency is not established.)
Risk of immunogenicity (Listed as a potential risk rather than a quantified event rate.)
Long-term safety not established (The source explicitly notes uncertainty about long-term safety.)

Generally well-tolerated (Reported by the source, but safety documentation is limited.)
Mild injection site reactions (Listed as a mild reported effect.)
Transient fatigue (Listed as a reported transient effect.)

+2 więcej

Mild gastrointestinal upset (Described by the source as rare.)
Limited documented side-effect data (The source indicates that adverse-effect reporting is incomplete.)

Podsumowanie researchu

The supplied research narrative gives greatest weight to laboratory and animal data. It cites a 2003 report by Khavinson and colleagues on telomerase activity and telomere changes in cultured human fibroblasts, plus a 2025 review discussing geroprotective and neuroendocrine research. Animal studies are described as reporting lifespan and tumor-incidence findings. Human evidence is characterized as limited, often small or open-label, and not independently replicated at the scale needed to prove lifespan extension or reliable telomere-length effects in people.

The supplied research summary places Cartalax in a preclinical evidence category. It cites in-vitro and animal findings, including a 2023 review that discusses AED among peptides relevant to chondrogenic differentiation and cartilage-cell signaling. Reported Russian literature describes cartilage-protective and matrix-related effects, while the source also notes limited independent Western validation and no human clinical trials. Overall, the evidence supports biological plausibility in experimental systems, not demonstrated human benefit.

Referencje

PubMed PubMed

+2 więcej

WikipediaEpitalon Springer

Peptibase peptides Peptibase peptides

+1 więcej

Peptibase peptides

Pełny profil

Zobacz szczegóły